![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Medicine and the Cancer Center, University of California, San Diego, La Jolla, California (K.K., R.S., G.S., A.H., S.B.H); and Globomax, Inc., Hanover, Maryland (M.R.)
Human tumor cells lines with acquired resistance to cisplatin (DDP) and carboplatin (CBDCA) are often cross-resistant to copper and vice versa, and some DDP-resistant cells overexpress the copper export pump ATP7B. We sought to demonstrate that ATP7B directly mediates resistance to DDP and CBDCA by stably transfecting human carcinoma cells with a vector designed to express ATP7B. Increased expression of ATP7B rendered all three cell lines tested more resistant to a 1-h exposure to DDP (1.6–2.6-fold), CBDCA (1.5–1.6-fold), and copper (1.2–1.4-fold). The effect of ATP7B on the cellular pharmacology of 64Cu and [14C]CBDCA was investigated in more detail using one cell pair (2008 cells transfected with an empty vector or an ATP7B-expressing vector). In the 2008/ATP7B subline, steady-state copper levels were decreased under both basal and copper-supplemented conditions, as was steady-state CBDCA content upon exposure to 50 µM [14C]CBDCA. Over the first 5 min, the average rate of accumulation of copper and CBCDA in the 2008/ATP7B cells was reduced by 37 and 61%, respectively. Efflux was more rapid from 2008/ATP7B cells for both copper and CBDCA. Two-compartment modeling indicated that the second phase of efflux was increased by a factor of 3.9-fold for CBCDA and to an even greater extent for copper. We conclude that expression of ATP7B regulates sensitivity to CBDCA as well as to DDP and copper and that a transporter that normally mediates copper homeostasis modulates the cellular pharmacology of CBDCA.
Address correspondence to: Dr. Stephen B. Howell, Department of Medicine 0058, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0058. E-mail: showell{at}ucsd.edu
This article has been cited by other articles:
|
|
 |
|
  R. Safaei, S. Otani, B. J. Larson, M. L. Rasmussen, and S. B. Howell Transport of Cisplatin by the Copper Efflux Transporter ATP7B Mol. Pharmacol., February 1, 2008; 73(2): 461 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P de Bie, P Muller, C Wijmenga, and L W J Klomp Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes J. Med. Genet., November 1, 2007; 44(11): 673 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lutsenko, N. L. Barnes, M. Y. Bartee, and O. Y. Dmitriev Function and Regulation of Human Copper-Transporting ATPases Physiol Rev, July 1, 2007; 87(3): 1011 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gaiddon, P. Jeannequin, P. Bischoff, M. Pfeffer, C. Sirlin, and J. P. Loeffler Ruthenium (II)-Derived Organometallic Compounds Induce Cytostatic and Cytotoxic Effects on Mammalian Cancer Cell Lines through p53-Dependent and p53-Independent Mechanisms J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1403 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Safaei, B. J. Larson, T. C. Cheng, M. A. Gibson, S. Otani, W. Naerdemann, and S. B. Howell Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells Mol. Cancer Ther., October 1, 2005; 4(10): 1595 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Safaei, K. Katano, B. J. Larson, G. Samimi, A. K. Holzer, W. Naerdemann, M. Tomioka, M. Goodman, and S. B. Howell Intracellular Localization and Trafficking of Fluorescein-Labeled Cisplatin in Human Ovarian Carcinoma Cells Clin. Cancer Res., January 15, 2005; 11(2): 756 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-S. Song, N. Savaraj, Z. H. Siddik, P. Liu, Y. Wei, C. J. Wu, and M. T. Kuo Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells Mol. Cancer Ther., December 1, 2004; 3(12): 1543 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Guo, K. Smith, and M. J. Petris Cisplatin Stabilizes a Multimeric Complex of the Human Ctr1 Copper Transporter: REQUIREMENT FOR THE EXTRACELLULAR METHIONINE-RICH CLUSTERS J. Biol. Chem., November 5, 2004; 279(45): 46393 - 46399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Morgan, R. Tsivkovskii, Y. A. Kosinsky, R. G. Efremov, and S. Lutsenko The Distinct Functional Properties of the Nucleotide-binding Domain of ATP7B, the Human Copper-transporting ATPase: ANALYSIS OF THE WILSON DISEASE MUTATIONS E1064A, H1069Q, R1151H, AND C1104F J. Biol. Chem., August 27, 2004; 279(35): 36363 - 36371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Samimi, R. Safaei, K. Katano, A. K. Holzer, M. Rochdi, M. Tomioka, M. Goodman, and S. B. Howell Increased Expression of the Copper Efflux Transporter ATP7A Mediates Resistance to Cisplatin, Carboplatin, and Oxaliplatin in Ovarian Cancer Cells Clin. Cancer Res., July 15, 2004; 10(14): 4661 - 4669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Samimi, K. Katano, A. K. Holzer, R. Safaei, and S. B. Howell Modulation of the Cellular Pharmacology of Cisplatin and Its Analogs by the Copper Exporters ATP7A and ATP7B Mol. Pharmacol., July 1, 2004; 66(1): 25 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Katano, R. Safaei, G. Samimi, A. Holzer, M. Tomioka, M. Goodman, and S. B. Howell Confocal Microscopic Analysis of the Interaction between Cisplatin and the Copper Transporter ATP7B in Human Ovarian Carcinoma Cells Clin. Cancer Res., July 1, 2004; 10(13): 4578 - 4588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Kruh Lustrous Insights into Cisplatin Accumulation: Copper Transporters Clin. Cancer Res., December 1, 2003; 9(16): 5807 - 5809. [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
